Professor Steve Wilton - Foundation Chair in Molecular Therapy



Professor Steve Wilton

Contact Details

Office: Murdoch Campus, Building 390, Room 2.011
Phone Number: +61 8 9360 2305
Fax Number: +61 8 9360 7238
Mailing Address: Centre for Comparative Genomics, Murdoch University, 90 South Street, Perth WA 6150, Australia
E-Mail Address: swilton@ccg.murdoch.edu.au

Information

Qualifications

PhD, BSc (Hons), University of Adelaide.

Research Interests

Molecular genetics, Antisense oligonucleotide technologies, Gene Therapy, Genetic Therapies, Exon skipping, Splice switching, Muscle repair and regeneration, Inherited neuromuscular diseases, Duchenne muscular dystrophy, spinal muscular atrophy

Publications

Book Chapter

  1. (2012) Adkin C, Fletcher S and Wilton SD. Optimizing splice-switching oligomer sequences using 2'-o-methyl phosphorothioate chemistry. Exon Skipping: Methods and Protocols. Aartsma-Rus A. United States, Humana Press. 867: 169-188.

Fully Refereed Journals

  1. (2014) Wilton SD, Fletcher S and Flanigan KM, Dystrophin as a therapeutic biomarker: Are we ignoring data from the past? Neuromuscul Disord 24: 463-466.
  2. (2014) Luo YB, Mastaglia FL and Wilton SD, Normal and aberrant splicing of LMNA. J Med Genet 51: 215-223.
  3. (2014) Greer KL, Lochmuller H, Flanigan K, Fletcher S and Wilton SD, Targeted exon skipping to correct exon duplications in the dystrophin gene. Mol Ther Nucleic Acids 3: e155.
  4. (2013) Rojana-Udomsart A, Mitrpant C, Bundell C, Price L, Luo YB, Fabian V, Wilton SD, Hollingsworth P and Mastaglia FL, Complement-mediated muscle cell lysis: a possible mechanism of myonecrosis in anti-SRP associated necrotizing myopathy (ASANM). J Neuroimmunol 264: 65-70.
  5. (2013) Pigozzo SR, Da Re L, Romualdi C, Mazzara PG, Galletta E, Fletcher S, Wilton SD, Vitiello L. Revertant Fibers in the mdx Murine Model of Duchenne Muscular Dystrophy: An Age- and Muscle-Related Reappraisal. PLoS One 8(8): e72147.
  6. (2013) Luo YB, Mitrpant C, Johnsen R, Fabian V, Needham M, Fletcher S, Wilton SD, Mastaglia FL. Investigation of splicing changes and post-translational processing of LMNA in sporadic inclusion body myositis. Int J Clin Exp Pathol 6(9): 1723-33.
  7. (2013) Zhou H, Janghra N, Mitrpant C, Dickinson RL, Anthony K, Price L, Eperon IC, Wilton SD, Morgan J and Muntoni F A novel morpholino oligomer targeting ISS-N1 improves rescue of severe spinal muscular atrophy transgenic mice. Hum Gene Ther 24(3): 331-342.
  8. (2013) Tremblay JP, Xiao X, Aartsma-Rus A, Barbas C, Blau HM, Bogdanove AJ, Boycott K, Braun S, Breakefield XO, Bueren JA, Buschmann M, Byrne BJ, Calos M, Cathomen T, Chamberlain J, Chuah M, Cornetta K, Davies KE, Dickson JG, Duchateau P, Flotte TR, Gaudet D, Gersbach CA, Gilbert R, Glorioso J, Herzog RW, High KA, Huang W, Huard J, Joung JK, Liu D, Liu D, Lochmuller H, Lustig L, Martens J, Massie B, Mavilio F, Mendell JR, Nathwani A, Ponder K, Porteus M, Puymirat J, Samulski J, Takeda S, Thrasher A, Vandendriessche T, Wei Y, Wilson JM, Wilton SD, Wolfe JH and Gao G Translating the genomics revolution: the need for an international gene therapy consortium for monogenic diseases. Mol Ther 21(2): 266-268.
  9. (2013) Rojana-udomsart A, Mitrpant C, James I, Witt C, Needham M, Day T, Kiers L, Corbett A, Martinez P, Wilton SD and Mastaglia FL Analysis of HLA-DRB3 alleles and supertypical genotypes in the MHC Class II region in sporadic inclusion body myositis. J Neuroimmunol 254(1-2): 174-177.
  10. (2013) Qiu W, Pham K, James I, Nolan D, Castley A, Christiansen FT, Czarniak P, Luo Y, Wu J, Garlepp M, Wilton SD, Carroll WM, Mastaglia FL and Kermode AG The influence of non-HLA gene polymorphisms and interactions on disease risk in a Western Australian multiple sclerosis cohort. J Neuroimmunol, 10.1016/j.jneuroim.2013.04.022.
  11. (2013) Plummer PN, Freeman R, Taft RJ, Vider J, Sax M, Umer BA, Gao D, Johns C, Mattick JS, Wilton SD, Ferro V, McMillan NA, Swarbrick A, Mittal V and Mellick AS MicroRNAs regulate tumor angiogenesis modulated by endothelial progenitor cells. Cancer Res 73(1): 341-352.
  12. (2013) Moorwood C, Soni N, Patel G, Wilton SD and Khurana TS A cell-based high-throughput screening assay for posttranscriptional utrophin upregulation. J Biomol Screen 18(4): 400-406.
  13. (2013) Mitrpant C, Porensky P, Zhou H, Price L, Muntoni F, Fletcher S, Wilton SD and Burghes AH Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy. PLoS One 8(4): e62114.
  14. (2012) Porensky PN, Mitrpant C, McGovern VL, Bevan AK, Foust KD, Kaspar BK, Wilton SD and Burghes AH A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse. Hum Mol Genet 21(7): 1625-1638.
  15. (2012) Fletcher S, Adkin CF, Meloni P, Wong B, Muntoni F, Kole R, Fragall C, Greer K, Johnsen R and Wilton SD Targeted exon skipping to address "leaky" mutations in the dystrophin gene. Mol Ther Nucleic Acids 1: e48.
  16. (2012) Barrett LW, Fletcher S and Wilton SD Regulation of eukaryotic gene expression by the untranslated gene regions and other non-coding elements. Cell Mol Life Sci 69(21): 3613-3634.
  17. (2012) Anderton RS, Price LL, Turner BJ, Meloni BP, Mitrpant C, Mastaglia FL, Goh C, Wilton SD and Boulos S Co-regulation of survival of motor neuron and Bcl-xL expression: implications for neuroprotection in spinal muscular atrophy. Neuroscience 220: 228-236.
  18. (2012) Adkin CF, Meloni PL, Fletcher S, Adams AM, Muntoni F, Wong B and Wilton SD Multiple exon skipping strategies to by-pass dystrophin mutations. Neuromuscul Disord 22(4): 297-305.
  19. (2011) Wilton SD and Fletcher S RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes. Curr Gene Ther 11(4): 259-275.
  20. (2011) Vanderplanck C, Ansseau E, Charron S, Stricwant N, Tassin A, Laoudj-Chenivesse D, Wilton SD, Coppee F and Belayew A The FSHD atrophic myotube phenotype is caused by DUX4 expression. PLoS One 6(10): e26820.
  21. (2011) Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, Takeda S, Wilton SD, Wolff JA, Wooddell CI, Xiao X and Tremblay JP Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol Ther 19(5): 830-840.
  22. (2011) Laing NG, Davis MR, Bayley K, Fletcher S and Wilton SD Molecular diagnosis of duchenne muscular dystrophy: past, present and future in relation to implementing therapies. Clin Biochem Rev 32(3): 129-134.
  23. (2011) Fragall CT, Adams AM, Johnsen RD, Kole R, Fletcher S and Wilton SD Mismatched single stranded antisense oligonucleotides can induce efficient dystrophin splice switching. BMC Med Genet 12: 141.
  24. (2011) Cirak S, Arechavala-Gomeza V, Guglieri M, Feng L, Torelli S, Anthony K, Abbs S, Garralda ME, Bourke J, Wells DJ, Dickson G, Wood MJ, Wilton SD, Straub V, Kole R, Shrewsbury SB, Sewry C, Morgan JE, Bushby K and Muntoni F Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. Lancet 378(9791): 595-605.
  25. (2011) Both G, Alexander I, Fletcher S, Nicolson TJ, Rasko JE, Wilton SD and Symonds G Gene therapy: therapeutic applications and relevance to pathology. Pathology 43(6): 642-656.
  26. (2011) Berger J, Berger S, Jacoby AS, Wilton SD and Currie PD Evaluation of exon-skipping strategies for Duchenne muscular dystrophy utilizing dystrophin-deficient zebrafish. J Cell Mol Med 15(12): 2643-2651.
  27. (2011) Basu U, Lozynska O, Moorwood C, Patel G, Wilton SD and Khurana TS Translational regulation of utrophin by miRNAs. PLoS One 6(12): e29376.
  28. (2010) Wilton SD and Fletcher S Splice modification to restore functional dystrophin synthesis in Duchenne muscular dystrophy. Curr Pharm Des 16(8): 988-1001.
  29. (2010) Popplewell LJ, Adkin C, Arechavala-Gomeza V, Aartsma-Rus A, de Winter CL, Wilton SD, Morgan JE, Muntoni F, Graham IR and Dickson G Comparative analysis of antisense oligonucleotide sequences targeting exon 53 of the human DMD gene: Implications for future clinical trials. Neuromuscul Disord 20(2): 102-110.
  30. (2010) Lau JY, Oliver BG, Baraket M, Beckett EL, Hansbro NG, Moir LM, Wilton SD, Williams C, Foster PS, Hansbro PM, Black JL and Burgess JK Fibulin-1 is increased in asthma--a novel mediator of airway remodeling? PLoS One 5(10): e13360.
  31. (2010) Goyenvalle A, Babbs A, Powell D, Kole R, Fletcher S, Wilton SD and Davies KE Prevention of dystrophic pathology in severely affected dystrophin/utrophin-deficient mice by morpholino-oligomer-mediated exon-skipping. Mol Ther 18(1): 198-205.
  32. (2010) Forrest S, Meloni PL, Muntoni F, Kim J, Fletcher S and Wilton SD Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations. Neuromuscul Disord 20(12): 810-816.
  33. (2010) Fletcher S, Adams AM, Johnsen RD, Greer K, Moulton HM and Wilton SD Dystrophin isoform induction in vivo by antisense-mediated alternative splicing. Mol Ther 18(6): 1218-1223.
  34. (2009) Sutherland GT, Halliday GM, Silburn PA, Mastaglia FL, Rowe DB, Boyle RS, O'Sullivan JD, Ly T, Wilton SD and Mellick GD Do polymorphisms in the familial Parkinsonism genes contribute to risk for sporadic Parkinson's disease? Mov Disord 24(6): 833-838.
  35. (2009) Mitrpant C, Fletcher S and Wilton SD Personalised genetic intervention for Duchenne muscular dystrophy: antisense oligomers and exon skipping. Curr Mol Pharmacol 2(1): 110-121.
  36. (2009) Mitrpant C, Fletcher S, Iversen PL and Wilton SD By-passing the nonsense mutation in the 4 CV mouse model of muscular dystrophy by induced exon skipping. J Gene Med 11(1): 46-56.
  37. (2009) Mitrpant C, Adams AM, Meloni PL, Muntoni F, Fletcher S and Wilton SD Rational design of antisense oligomers to induce dystrophin exon skipping. Mol Ther 17(8): 1418-1426.
  38. (2009) Madden HR, Fletcher S, Davis MR and Wilton SD Characterization of a complex Duchenne muscular dystrophy-causing dystrophin gene inversion and restoration of the reading frame by induced exon skipping. Hum Mutat 30(1): 22-28.
  39. (2009) Kinali M, Arechavala-Gomeza V, Feng L, Cirak S, Hunt D, Adkin C, Guglieri M, Ashton E, Abbs S, Nihoyannopoulos P, Garralda ME, Rutherford M, McCulley C, Popplewell L, Graham IR, Dickson G, Wood MJ, Wells DJ, Wilton SD, Kole R, Straub V, Bushby K, Sewry C, Morgan JE and Muntoni F Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol 8(10): 918-928.
  40. (2009) Doran P, Wilton SD, Fletcher S and Ohlendieck K Proteomic profiling of antisense-induced exon skipping reveals reversal of pathobiochemical abnormalities in dystrophic mdx diaphragm. Proteomics 9(3): 671-685.
  41. (2008) Wilton SD and Fletcher S Exon skipping and Duchenne muscular dystrophy: Hope, hype and how feasible? Neurol India 56(3): 254-262.
  42. (2008) Wilton SD Exon skipping in Duchenne muscular dystrophy. Neuromuscul Disord 18(5): 431-432.
  43. (2008) Laws N, Cornford-Nairn RA, Irwin N, Johnsen R, Fletcher S, Wilton SD and Hoey AJ Long-term administration of antisense oligonucleotides into the paraspinal muscles of mdx mice reduces kyphosis. J Appl Physiol 105(2): 662-668.
  44. (2008) Gurvich OL, Tuohy TM, Howard MT, Finkel RS, Medne L, Anderson CB, Weiss RB, Wilton SD and Flanigan KM DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy. Ann Neurol 63(1): 81-89.
  45. (2007) Wilton SD, Fall AM, Harding PL, McClorey G, Coleman C, Fletcher S. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther15 (7):1288-1296.
  46. (2007) Wilton SD PTC124, nonsense mutations and Duchenne muscular dystrophy. Neuromuscul Disord 17(9-10): 719-720.
  47. (2007) Webb BT, van den Oord E, Akkari A, Wilton SD, Ly T, Duff R, Barnes KC, Carlsen K, Gerritsen J, Lenney W, Silverman M, Sly P, Sundy J, Tsanakas J, von Berg A, Whyte M, Blumenthal M, Vestbo J, Middleton L, Helms PJ, Anderson WH and Pillai SG Quantitative linkage genome scan for atopy in a large collection of Caucasian families. Hum Genet 121(1): 83-92.
  48. (2007) Moulton HM, Fletcher S, Neuman BW, McClorey G, Stein DA, Abes S, Wilton SD, Buchmeier MJ, Lebleu B and Iversen PL Cell-penetrating peptide-morpholino conjugates alter pre-mRNA splicing of DMD (Duchenne muscular dystrophy) and inhibit murine coronavirus replication in vivo. Biochem Soc Trans 35(Pt 4): 826-828.
  49. (2007) Harding PL, Fall AM, Honeyman K, Fletcher S and Wilton SD The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther 15(1): 157-166.
  50. (2007) Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD, Steinhaus JP, Moulton HM, Iversen PL and Wilton SD Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 15(9): 1587-1592.
  51. (2007) Arechavala-Gomeza V, Graham IR, Popplewell LJ, Adams AM, Aartsma-Rus A, Kinali M, Morgan JE, van Deutekom JC, Wilton SD, Dickson G, Muntoni F. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 18(9):798-810.
  52. (2007) Adams AM, Harding PL, Iversen PL, Coleman C, Fletcher S and Wilton SD Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol 8: 57.
  53. (2006) Wilton SD and Fletcher S Modification of pre-mRNA processing: application to dystrophin expression. Curr Opin Mol Ther 8(2): 130-135.
  54. (2006) Wilton SD and Fletcher S Redirecting splicing to address dystrophin mutations: molecular by-pass surgery. Prog Mol Subcell Biol 44: 161-197.
  55. (2006) McClorey G, Moulton HM, Iversen PL, Fletcher S and Wilton SD Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 13(19): 1373-1381.
  56. (2006) McClorey G, Fall AM, Moulton HM, Iversen PL, Rasko JE, Ryan M, Fletcher S and Wilton SD Induced dystrophin exon skipping in human muscle explants. Neuromuscul Disord 16(9-10): 583-590.
  57. (2006) Fletcher S, Honeyman K, Fall AM, Harding PL, Johnsen RD and Wilton SD Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8(2): 207-216.
  58. (2006) Fall AM, Johnsen R, Honeyman K, Iversen P, Fletcher S and Wilton SD Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther 4: 3.
  59. (2006) Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD, Partridge TA and Lu QL Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12(2): 175-177.
  60. (2005) Yu Y, Wyszynski DF, Waterworth DM, Wilton SD, Barter PJ, Kesaniemi YA, Mahley RW, McPherson R, Waeber G, Bersot TP, Ma Q, Sharma SS, Montgomery DS, Middleton LT, Sundseth SS, Mooser V, Grundy SM and Farrer LA Multiple QTLs influencing triglyceride and HDL and total cholesterol levels identified in families with atherogenic dyslipidemia. J Lipid Res 46(10): 2202-2213.
  61. (2005) Wilton SD and Fletcher S Antisense oligonucleotides in the treatment of Duchenne muscular dystrophy: Where are we now? Neuromuscul Disord 15(6): 399-402.
  62. (2005) Wilton SD and Fletcher S Antisense oligonucleotides, exon skipping and the dystrophin gene transcript. Acta Myol 24(3): 222-229.
  63. (2005) Wilton SD and Fletcher S RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes. Curr Gene Ther 5(5): 467-483.
  64. (2005) McClorey G, Fletcher S and Wilton SD Splicing intervention for Duchenne muscular dystrophy. Curr Opin Pharmacol 5(5): 529-534.
  65. (2005) Gebski BL, Errington SJ, Johnsen RD, Fletcher S and Wilton SD Terminal antisense oligonucleotide modifications can enhance induced exon skipping. Neuromuscul Disord 15(9-10): 622-629.
  66. (2003) Wells KE, Fletcher S, Mann CJ, Wilton SD and Wells DJ Enhanced in vivo delivery of antisense oligonucleotides to restore dystrophin expression in adult mdx mouse muscle. FEBS Lett 552(2-3): 145-149.
  67. (2003) Lu QL, Mann CJ, Lou F, Bou-Gharios G, Morris GE, Xue SA, Fletcher S, Partridge TA and Wilton SD Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 9(8): 1009-1014.
  68. (2003) Gebski BL, Mann CJ, Fletcher S and Wilton SD Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 12(15): 1801-1811.
  69. (2003) Errington SJ, Mann CJ, Fletcher S and Wilton SD Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. J Gene Med 5(6): 518-527.
  70. (2002) Mann CJ, Honeyman K, McClorey G, Fletcher S and Wilton SD Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 4(6): 644-654.
  71. (2001) Mann CJ, Honeyman K, Cheng AJ, Ly T, Lloyd F, Fletcher S, Morgan JE, Partridge TA and Wilton SD Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci U S A 98(1): 42-47.
  72. (2001) Loh NK, Woerly S, Bunt SM, Wilton SD, Harvey AR. The regrowth of axons within tissue defects in the CNS is promoted by implanted hydrogel matrices that contain BDNF and CNTF producing fibroblasts. Exp Neurol 170(1): 72-84.
  73. (2001) Fletcher S, Ly T, Duff RM, Mc CHJ and Wilton SD Cryptic splicing involving the splice site mutation in the canine model of Duchenne muscular dystrophy. Neuromuscul Disord 11(3): 239-243.
  74. (2001) Fletcher S, Carville KS, Howell JM, Mann CJ and Wilton SD Evaluation of a short interspersed nucleotide element in the 3' untranslated region of the defective dystrophin gene of dogs with muscular dystrophy. Am J Vet Res 62(12): 1964-1968.
  75. (2000) Nowak KJ, Walsh P, Jacob RL, Johnsen RD, Peverall J, McNally EM, Wilton SD, Kakulas BA and Laing NG Severe gamma-sarcoglycanopathy caused by a novel missense mutation and a large deletion. Neuromuscul Disord 10(2): 100-107.
  76. (2000) Lu QL, Morris GE, Wilton SD, Ly T, Artem'yeva OV, Strong P and Partridge TA Massive idiosyncratic exon skipping corrects the nonsense mutation in dystrophic mouse muscle and produces functional revertant fibers by clonal expansion. J Cell Biol 148(5): 985-996.
  77. (2000) Fletcher S, Wilton SD and Howell JM Gene therapy and molecular approaches to the treatment of hereditary muscular disorders. Curr Opin Neurol 13(5): 553-560.
  78. (1999) Wilton SD, Lloyd F, Carville K, Fletcher S, Honeyman K, Agrawal S and Kole R Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 9(5): 330-338.
  79. (1999) Tan P, Briner J, Boltshauser E, Davis MR, Wilton SD, North K, Wallgren-Pettersson C and Laing NG Homozygosity for a nonsense mutation in the alpha-tropomyosin slow gene TPM3 in a patient with severe infantile nemaline myopathy. Neuromuscul Disord 9(8): 573-579.
  80. (1999) Schatzberg SJ, Olby NJ, Breen M, Anderson LV, Langford CF, Dickens HF, Wilton SD, Zeiss CJ, Binns MM, Kornegay JN, Morris GE and Sharp NJ Molecular analysis of a spontaneous dystrophin 'knockout' dog. Neuromuscul Disord 9(5): 289-295.
  81. (1999) Schatzberg S, Olby N, Steingold S, Keene B, Atkins C, Meurs K, Solomon G, Goedegebuure SA, Wilton SD and Sharp N A polymerase chain reaction screening strategy for the promoter of the canine dystrophin gene. Am J Vet Res 60(9): 1040-1046.
  82. (1999) Pelin K, Hilpela P, Donner K, Sewry C, Akkari PA, Wilton SD, Wattanasirichaigoon D, Bang ML, Centner T, Hanefeld F, Odent S, Fardeau M, Urtizberea JA, Muntoni F, Dubowitz V, Beggs AH, Laing NG, Labeit S, de la Chapelle A and Wallgren-Pettersson C Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Proc Natl Acad Sci U S A 96(5): 2305-2310.
  83. (1999) Panegyres PK, Mamotte CD, Vasikaran SD, Wilton SD, Fabian V and Kakulas BA Butyrycholinesterase K variant and Alzheimer's disease. J Neurol 246(5): 369-370.
  84. (1999) Mastaglia FL, Nowak KJ, Stell R, Phillips BA, Edmondston JE, Dorosz SM, Wilton SD, Hallmayer J, Kakulas BA and Laing NG Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry 67(2): 174-179.
  85. (1999) Honeyman K, Carville KS, Howell JM, Fletcher S and Wilton SD Development of a snapback method of single-strand conformation polymorphism analysis for genotyping Golden Retrievers for the X-linked muscular dystrophy allele. Am J Vet Res 60(6): 734-737.
  86. (1998) Wilton SD, Honeyman K, Fletcher S and Laing NG Snapback SSCP analysis: engineered conformation changes for the rapid typing of known mutations. Hum Mutat 11(3): 252-258.
  87. (1998) Schatzberg SJ, Anderson LV, Wilton SD, Kornegay JN, Mann CJ, Solomon GG and Sharp NJ Alternative dystrophin gene transcripts in golden retriever muscular dystrophy. Muscle Nerve 21(8): 991-998.
  88. (1997) Wilton SD, Lim L, Dye D and Laing N Bandstab: a PCR-based alternative to cloning PCR products. Biotechniques 22(4): 642-645.
  89. (1997) Wilton SD, Dye DE and Laing NG Dystrophin gene transcripts skipping the mdx mutation. Muscle Nerve 20(6): 728-734.
  90. (1997) Wilton SD, Dye DE, Blechynden LM and Laing NG Revertant fibres: a possible genetic therapy for Duchenne muscular dystrophy? Neuromuscul Disord 7(5): 329-335.
  91. (1997) Tan P, Allen JG, Wilton SD, Akkari PA, Huxtable CR and Laing NG A splice-site mutation causing ovine McArdle's disease. Neuromuscul Disord 7(5): 336-342.
  92. (1997) Pelin K, Ridanpaa M, Donner K, Wilton SD, Krishnarajah J, Laing N, Kolmerer B, Millevoi S, Labeit S, de la Chapelle A and Wallgren-Petterson C Refined localisation of the genes for nebulin and titin on chromosome 2q allows the assignment of nebulin as a candidate gene for autosomal recessive nemaline myopathy. Eur J Hum Genet 5(4): 229-234.
  93. (1997) He K, Wilton SD, Tate ML and Murphy MP Characterization of the erythrocyte superoxide dismutase allozymes in the deer Cervus elaphus. Anim Genet 28(4): 299-301.
  94. (1996) Wilton SD, Lim L, Dorosz SD, Gunn HC, Eyre HJ, Callen DF and Laing NG Assignment of the human alpha-tropomyosin gene TPM4 to band 19p13.1 by fluorescence in situ hybridization. Cytogenet Cell Genet 72(4): 294-296.
  95. (1996) Wilton SD and Lim L Long-range PCR: synthesis of products independent of size. Trends Genet 12(11): 458.
  96. (1996) Stanton JL, Wilton SD and Laing NG Characterisation of the chicken Cu,Zn superoxide dismutase gene. DNA Seq 6(6): 357-360.
  97. (1996) Kakulas BA, Wilton SD, Fabian VA and Jones TM Apolipoprotein-E genotyping in diagnosis of Alzheimer's disease. Lancet 348(9025): 483.
  98. (1996) Hosler BA, Nicholson GA, Sapp PC, Chin W, Orrell RW, de Belleroche JS, Esteban J, Hayward LJ, McKenna-Yasek D, Yeung L, Cherryson AK, Dench JE, Wilton SD, Laing NG, Horvitz RH and Brown RH, Jr. Three novel mutations and two variants in the gene for Cu/Zn superoxide dismutase in familial amyotrophic lateral sclerosis. Neuromuscul Disord 6(5): 361-366.
  99. (1996) Fabian VA, Jones TM, Wilton SD, Dench JE, Davis MR, Lim L and Kakulas BA Alzheimer's disease and apolipoprotein E genotype in Western Australia: an autopsy-verified series. Med J Aust 165(2): 77-80.
  100. (1996) Bartlett RJ, Winand NJ, Secore SL, Singer JT, Fletcher S, Wilton SD, Bogan DJ, Metcalf-Bogan JR, Bartlett WT, Howell JM, Cooper BJ and Kornegay JN Mutation segregation and rapid carrier detection of X-linked muscular dystrophy in dogs. Am J Vet Res 57(5): 650-654.
  101. (1995) Wilton SD, Eyre H, Akkari PA, Watkins HC, MacRae C, Laing NG and Callen DC Assignment of the human a-tropomyosin gene TPM3 to 1q22-->q23 by fluorescence in situ hybridisation. Cytogenet Cell Genet 68(1-2): 122-124.
  102. (1995) Wilton SD and Lim L Rapid identification of ApoE alleles by multiple-single-strand conformation polymorphism (SSCP) analysis. Trends Genet 11(9): 341.
  103. (1995) Langdon JS, Masters A, Wilton SD and Nel S Bizarre protistan organism from the skin of mahi mahi. J Fish Disease: 481-494.
  104. (1995) Laing NG, Wilton SD, Akkari PA, Dorosz S, Boundy K, Kneebone C, Blumbergs P, White S, Watkins H, Love DR and et al. A mutation in the alpha tropomyosin gene TPM3 associated with autosomal dominant nemaline myopathy NEM1. Nat Genet 10(2): 249.
  105. (1995) Laing NG, Laing BA, Meredith C, Wilton SD, Robbins P, Honeyman K, Dorosz S, Kozman H, Mastaglia FL and Kakulas BA Autosomal dominant distal myopathy: linkage to chromosome 14. Am J Hum Genet 56(2): 422-427.
  106. (1995) Hunt CC, Eyre HJ, Akkari PA, Meredith C, Dorosz SM, Wilton SD, Callen DF, Laing NG and Baker E Assignment of the human beta tropomyosin gene (TPM2) to band 9p13 by fluorescence in situ hybridisation. Cytogenet Cell Genet 71(1): 94-95.
  107. (1995) Eyre H, Akkari PA, Wilton SD, Callen DC, Baker E and Laing NG Assignment of the human skeletal muscle alpha-tropomyosin gene (TPM1) to band 15q22 by fluorescence in situ hybridization. Cytogenet Cell Genet 69(1-2): 15-17.
  108. (1994) Wilton SD, Chandler DC, Kakulas BA and Laing NG Identification of a point mutation and germinal mosaicism in a Duchenne muscular dystrophy family. Hum Mutat 3(2): 133-140.
  109. (1994) Suthers G, Laing N, Wilton SD, Dorosz S and Waddy H "Sporadic" motoneuron disease due to familial SOD1 mutation with low penetrance. Lancet 344(8939-8940): 1773.
  110. (1994) Akkari PA, Eyre HJ, Wilton SD, Callen DF, Lane SA, Meredith C, Kedes L and Laing NG Assignment of the human skeletal muscle alpha actin gene (ACTA1) to 1q42 by fluorescence in situ hybridisation. Cytogenet Cell Genet 65(4): 265-267.
  111. (1993) Wilton SD, Johnsen RD, Pedretti JR and Laing NG Two distinct mutations in a single dystrophin gene: identification of an altered splice-site as the primary Becker muscular dystrophy mutation. Am J Med Genet 46(5): 563-569.
  112. (1993) Wilton SD, Goldblatt J and Laing NG Verification of carrier status for Becker muscular dystrophy from analysis of a blighted ovum. Prenat Diagn 13(8): 757-762.
  113. (1993) Laing NG, Laing BA, Meredith C, Wilton SD, Mastaglia FL, Robbins P, Honeyman K, Dorosz S and Kakulas BA An autosomal dominant distal myopathy - preliminary linkage to chromosome 14. The Clinical Biochemist Reviews 14.
  114. (1993) Eyre HJ, Akkari PA, Meredith C, Wilton SD, Callen DC, Kedes L and Laing NG Assignment of the human slow skeletal muscle troponin gene (TNNI1) to 1q32 by fluorescence in situ hybridisation. Cytogenet Cell Genet 62(2-3): 181-182.
  115. (1992) Wilton SD and Cousins D Detection and identification of multiple mycobacterial pathogens by DNA amplification in a single tube. PCR Methods Appl 1(4): 269-273.
  116. (1992) Cousins DV, Wilton SD, Francis BR and Gow BL Use of polymerase chain reaction for rapid diagnosis of tuberculosis. J Clin Microbiol 30(1): 255-258.
  117. (1991) Cousins DV, Wilton SD and Francis BR Use of DNA amplification for the rapid identification of Mycobacterium bovis. Vet Microbiol 27(2): 187-195.
  118. (1985) Wilton SD, Crocker LA and Rogers GE Isolation and characterisation of keratin mRNA from the scale epidermis of the embryonic chick. Biochim Biophys Acta 824(3): 201-208.
  119. (1984) Gregg K, Wilton SD, Parry DA and Rogers GE A comparison of genomic coding sequences for feather and scale keratins: structural and evolutionary implications. EMBO J 3(1): 175-178.
  120. (1983) Gregg K, Wilton SD, Rogers GE and Molloy PL Manipulation and expression of genes in eukaryotes. 65-72.